Cargando…
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
IN BRIEF New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium–glucose cotransporter...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640890/ https://www.ncbi.nlm.nih.gov/pubmed/31371851 http://dx.doi.org/10.2337/cd18-0064 |